Skip to main content

Advertisement

Table 3 Demographic and clinicopathologic characteristics of patients recruited to the ongoing phase I trial of HER2-pulsed DC1 vaccination in HER2pos IBC patients with residual disease following neoadjuvant trastuzumab and chemotherapy (NCT02061423)

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Subject Age, y HLA Race Menopausal status ER PR HER2 T + C regimen Surgery yp stage
26113-01 67 A2 White Postmenopausal +, 30 % +, 5 % 3+, >90 % AC/TH MRM T1b N2a
26113-02 35 A2 White Premenopausal +, 30 % +, 4 % 2+, FISH + AC/TH MRM T2 N2a
26113-03 45 - White Premenopausal +, 84 % -, 3 % 3+, >10 % AC/TH MRM Tis N0
26113-04 55 - White Postmenopausal −, 0 % -, 0 % 3+, >10 % TC MRM T1c N1mi
  1. HER2 human epidermal growth factor receptor 2, DC1 type 1-polarized dendritic cell, IBC invasive breast cancer, HLA human leukocyte antigen (A2 yes/no), ER estrogen receptor, PR progesterone receptor, T + C trastuzumab and chemotherapy, yp post-neoadjuvant pathologic stage, AC/TH Adriamycin/Cyclophosphamide/Taxol/Herceptin, MRM modified radical mastectomy, FISH fluorescence in situ hybridization, TC Taxotere, Cyclophosphamide